{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:08:03Z","timestamp":1794056883057,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C17375\/A19482"],"award-info":[{"award-number":["C17375\/A19482"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["Drug Discovery Committee Specialist Unit Agreement"],"award-info":[{"award-number":["Drug Discovery Committee Specialist Unit Agreement"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We evaluated the therapeutic potential of combining the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 with the mitochondrial respiratory Complex I inhibitor IACS-010759, for the treatment of diffuse large B-cell lymphoma (DLBCL), a potential clinically actionable strategy to target tumour metabolism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>AZD3965 and IACS-010759 sensitivity were determined in DLBCL cell lines and tumour xenograft models. Lactate concentrations, oxygen consumption rate and metabolomics were examined as mechanistic endpoints. In vivo plasma concentrations of IACS-010759 in mice were determined by LC-MS to select a dose that reflected clinically attainable concentrations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In vitro, the combination of AZD3965 and IACS-010759 is synergistic and induces DLBCL cell death, whereas monotherapy treatments induce a cytostatic response. Significant anti-tumour activity was evident in Toledo and Farage models when the two inhibitors were administered concurrently despite limited or no effect on the growth of DLBCL xenografts as monotherapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first study to examine a combination of two distinct approaches to targeting tumour metabolism in DLBCL xenografts. Whilst nanomolar concentrations of either AZD3965 or IACS-010759 monotherapy demonstrate anti-proliferative activity against DLBCL cell lines in vitro, appreciable clinical activity in DLBCL patients may only be realised through their combined use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-01848-w","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T19:03:01Z","timestamp":1653591781000},"page":"937-947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"127","author":[{"given":"Richard A.","family":"Noble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Herendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Dragoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-8851","authenticated-orcid":false,"given":"Hector C.","family":"Keun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Vellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Marszalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3644-6157","authenticated-orcid":false,"given":"Stephen R.","family":"Wedge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"1848_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41416-019-0621-4","volume":"122","author":"F Aroldi","year":"2020","unstructured":"Aroldi F, Lord SR. Window of opportunity clinical trial designs to study cancer metabolism. Br J Cancer. 2020;122:45\u201351.","journal-title":"Br J Cancer"},{"key":"1848_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev-cancerbio-030419-033635","volume":"4","author":"BJ Van den Eynde","year":"2020","unstructured":"Van den Eynde BJ, van Baren N, Baurain J-F. Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma? Annu Rev Cancer Biol. 2020;4:241\u201356.","journal-title":"Annu Rev Cancer Biol"},{"key":"1848_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-019-0666-4","volume":"122","author":"AL Harris","year":"2020","unstructured":"Harris AL. Development of cancer metabolism as a therapeutic target: new pathways, patient studies, stratification and combination therapy. Br J Cancer. 2020;122:1\u20133.","journal-title":"Br J Cancer"},{"key":"1848_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1470-2045(15)00027-3","volume":"16","author":"S Kordes","year":"2015","unstructured":"Kordes S, Pollak MN, Zwinderman AH, Math\u00f4t RA, Weterman MJ, Beeker A, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16:839\u201347.","journal-title":"Lancet Oncol"},{"key":"1848_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten M, Nollen EAA, R\u00f6hrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18:379\u2013401.","journal-title":"Nat Rev Drug Discov"},{"key":"1848_CR6","doi-asserted-by":"publisher","first-page":"69219","DOI":"10.18632\/oncotarget.18215","volume":"8","author":"NJ Curtis","year":"2017","unstructured":"Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H, et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt\u2019s lymphoma anti-tumour activity. Oncotarget. 2017;8:69219\u201336.","journal-title":"Oncotarget"},{"key":"1848_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/0008-5472.CAN-13-2034","volume":"74","author":"JR Doherty","year":"2014","unstructured":"Doherty JR, Yang C, Scott KEN, Cameron MD, Fallahi M, Li W, et al. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res. 2014;74:908\u201320.","journal-title":"Cancer Res"},{"key":"1848_CR8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/1078-0432.CCR-13-2270","volume":"20","author":"R Polanski","year":"2014","unstructured":"Polanski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014;20:926\u201337.","journal-title":"Clin Cancer Res"},{"key":"1848_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12907-017-0067-7","volume":"17","author":"A Latif","year":"2017","unstructured":"Latif A, Chadwick AL, Kitson SJ, Gregson HJ, Sivalingam VN, Bolton J, et al. Monocarboxylate transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer. BMC Clin Pathol. 2017;17:27.","journal-title":"BMC Clin Pathol"},{"key":"1848_CR10","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.celrep.2016.01.057","volume":"14","author":"CS Hong","year":"2016","unstructured":"Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, et al. MCT1 modulates cancer cell pyruvate export and growth of tumours that co-express MCT1 and MCT4. Cell Rep. 2016;14:1590\u2013601.","journal-title":"Cell Rep."},{"key":"1848_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94:604\u201316.","journal-title":"Am J Hematol"},{"key":"1848_CR12","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3324\/haematol.2016.163030","volume":"102","author":"RA Noble","year":"2017","unstructured":"Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017;102:1247\u201357.","journal-title":"Haematologica"},{"key":"1848_CR13","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-17-1253","volume":"17","author":"M Quanz","year":"2018","unstructured":"Quanz M, Bender E, Kopitz C, Gr\u00fcnewald S, Schlicker A, Schwede W, et al. Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance. Mol Cancer Therapeutics. 2018;17:2285.","journal-title":"Mol Cancer Therapeutics"},{"key":"1848_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","volume":"11","author":"SE Weinberg","year":"2015","unstructured":"Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015;11:9\u201315.","journal-title":"Nat Chem Biol"},{"key":"1848_CR15","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24:2482\u201390.","journal-title":"Clin Cancer Res"},{"key":"1848_CR16","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.redox.2018.101073","volume":"25","author":"M Lee","year":"2019","unstructured":"Lee M, Hirpara JL, Eu J-Q, Sethi G, Wang L, Goh B-C, et al. Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumours. Redox Biol. 2019;25:101073.","journal-title":"Redox Biol"},{"key":"1848_CR17","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036\u201346.","journal-title":"Nat Med"},{"key":"1848_CR18","doi-asserted-by":"publisher","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:eaau1167.","journal-title":"Sci Transl Med"},{"key":"1848_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/cdd.2016.116","volume":"24","author":"E Norberg","year":"2017","unstructured":"Norberg E, Lako A, Chen P-H, Stanley IA, Zhou F, Ficarro SB, et al. Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death Differ. 2017;24:251\u201362.","journal-title":"Cell Death Differ"},{"key":"1848_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.yexcr.2017.04.029","volume":"356","author":"RA Cairns","year":"2017","unstructured":"Cairns RA, Mak TW. Fire and water: Tumour cell adaptation to metabolic conditions. Exp Cell Res. 2017;356:204\u20138.","journal-title":"Exp Cell Res"},{"key":"1848_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.celrep.2018.12.043","volume":"26","author":"Y Sun","year":"2019","unstructured":"Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, et al. Functional genomics reveals synthetic lethality between phosphogluconate dehydrogenase and oxidative phosphorylation. Cell Rep. 2019;26:469\u201382.e465.","journal-title":"Cell Rep."},{"key":"1848_CR22","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.celrep.2020.01.039","volume":"30","author":"N Oshima","year":"2020","unstructured":"Oshima N, Ishida R, Kishimoto S, Beebe K, Brender JR, Yamamoto K, et al. Dynamic imaging of LDH inhibition in tumours reveals rapid in vivo metabolic rewiring and vulnerability to combination therapy. Cell Rep. 2020;30:1798\u2013810. e1794.","journal-title":"Cell Rep."},{"key":"1848_CR23","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2018.211011","volume":"104","author":"SW Hicks","year":"2019","unstructured":"Hicks SW, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas AJ, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumour activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019;104:1633\u20139.","journal-title":"Haematologica"},{"key":"1848_CR24","doi-asserted-by":"publisher","first-page":"e79602","DOI":"10.1371\/journal.pone.0079602","volume":"8","author":"N Bethge","year":"2013","unstructured":"Bethge N, Honne H, Hilden V, Tr\u00f8en G, Ekn\u00e6s M, Liest\u00f8l K, et al. Identification of highly methylated genes across various types of B-cell non-Hodgkin lymphoma. PLoS ONE. 2013;8:e79602\u2013e79602.","journal-title":"PLoS ONE"},{"key":"1848_CR25","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1073\/pnas.0611399104","volume":"104","author":"JM Polo","year":"2007","unstructured":"Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA. 2007;104:3207\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1848_CR26","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1182\/bloodadvances.2020003566","volume":"5","author":"AA Mensah","year":"2021","unstructured":"Mensah AA, Spriano F, Sartori G, Priebe V, Cascione L, Gaudio E, et al. Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Adv. 2021;5:2467\u201380.","journal-title":"Blood Adv"},{"key":"1848_CR27","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","volume":"111","author":"L Chen","year":"2008","unstructured":"Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230\u20137.","journal-title":"Blood"},{"key":"1848_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, Kryukov GV, Lo CC, McDonald ER, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"1848_CR29","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"1848_CR30","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555\u201377.","journal-title":"Br J Cancer"},{"key":"1848_CR31","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488\u2013W493.","journal-title":"Nucleic Acids Res"},{"key":"1848_CR32","doi-asserted-by":"publisher","first-page":"D478","DOI":"10.1093\/nar\/gkt1067","volume":"42","author":"T Jewison","year":"2014","unstructured":"Jewison T, Su Y, Disfany FM, Liang Y, Knox C, Maciejewski A, et al. SMPDB 2.0: big improvements to the small molecule pathway database. Nucleic Acids Res. 2014;42:D478\u2013484.","journal-title":"Nucleic Acids Res"},{"key":"1848_CR33","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1002\/cpbi.86","volume":"68","author":"J Chong","year":"2019","unstructured":"Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinforma. 2019;68:e86.","journal-title":"Curr Protoc Bioinforma"},{"key":"1848_CR34","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368:eaaw5473.","journal-title":"Science"},{"key":"1848_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","volume":"9","author":"GM Fischer","year":"2019","unstructured":"Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 2019;9:628\u201345.","journal-title":"Cancer Discov"},{"key":"1848_CR36","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1158\/1535-7163.MCT-13-1091","volume":"13","author":"BM Bola","year":"2014","unstructured":"Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014;13:2805\u201316.","journal-title":"Mol Cancer Ther"},{"key":"1848_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep45465","volume":"7","author":"S Heinz","year":"2017","unstructured":"Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H. Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation. Sci Rep. 2017;7:45465.","journal-title":"Sci Rep."},{"key":"1848_CR38","first-page":"581","volume":"22","author":"EA Burgess","year":"1962","unstructured":"Burgess EA, Sylv\u00e9n B. Glucose, lactate, and lactic dehydrogenase activity in normal interstitial fluid and that of solid mouse tumours. Cancer Res. 1962;22:581\u20138.","journal-title":"Cancer Res"},{"key":"1848_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.canlet.2016.11.040","volume":"388","author":"A Bastian","year":"2017","unstructured":"Bastian A, Matsuzaki S, Humphries KM, Pharaoh GA, Doshi A, Zaware N, et al. AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1alpha stabilization. Cancer Lett. 2017;388:149\u201357.","journal-title":"Cancer Lett"},{"key":"1848_CR40","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","volume":"24","author":"A Luengo","year":"2017","unstructured":"Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017;24:1161\u201380.","journal-title":"Cell Chem Biol"},{"key":"1848_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cam4.112","volume":"2","author":"P Ellinghaus","year":"2013","unstructured":"Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumour activities by inhibition of mitochondrial complex I. Cancer Med. 2013;2:611\u201324.","journal-title":"Cancer Med"},{"key":"1848_CR42","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ckel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, et al. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumour growth. Cancer Metab. 2015;3:1\u201316.","DOI":"10.1186\/s40170-015-0138-0"},{"key":"1848_CR43","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1124\/pr.119.018762","volume":"72","author":"MA Felmlee","year":"2020","unstructured":"Felmlee MA, Jones RS, Rodriguez-Cruz V, Follman KE, Morris ME. Monocarboxylate transporters (SLC16): function, regulation, and role in health and disease. Pharmacol Rev. 2020;72:466\u201385.","journal-title":"Pharmacol Rev"},{"key":"1848_CR44","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2019.37.15_suppl.3014","volume":"37","author":"TA Yap","year":"2019","unstructured":"Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, et al. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumours. J Clin Oncol. 2019;37:3014.","journal-title":"J Clin Oncol"},{"key":"1848_CR45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41416-019-0717-x","volume":"122","author":"M Beloueche-Babari","year":"2020","unstructured":"Beloueche-Babari M, Casals Galobart T, Delgado-Goni T, Wantuch S, Parkes HG, Tandy D, et al. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration. Br J Cancer. 2020;122:895\u2013903.","journal-title":"Br J Cancer"},{"key":"1848_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.mam.2012.05.003","volume":"34","author":"AP Halestrap","year":"2013","unstructured":"Halestrap AP. The SLC16 gene family\u2014structure, role and regulation in health and disease. Mol Asp Med. 2013;34:337\u201349.","journal-title":"Mol Asp Med"},{"key":"1848_CR47","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1200\/JCO.2021.39.15_suppl.3115","volume":"39","author":"SER Halford","year":"2021","unstructured":"Halford SER, Walter H, McKay P, Townsend W, Linton K, Heinzmann K, et al. Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). J Clin Oncol. 2021;39:3115.","journal-title":"J Clin Oncol"},{"key":"1848_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52112-w","volume":"9","author":"LR Viana","year":"2019","unstructured":"Viana LR, Tobar N, Busanello ENB, Marques AC, de Oliveira AG, Lima TI, et al. Leucine-rich diet induces a shift in tumour metabolism from glycolytic towards oxidative phosphorylation, reducing glucose consumption and metastasis in Walker-256 tumour-bearing rats. Sci Rep. 2019;9:15529.","journal-title":"Sci Rep."},{"key":"1848_CR49","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ccell.2019.12.011","volume":"37","author":"S Sivanand","year":"2020","unstructured":"Sivanand S, Vander Heiden MG. Emerging roles for branched-chain amino acid metabolism in cancer. Cancer Cell. 2020;37:147\u201356.","journal-title":"Cancer Cell"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01848-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01848-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01848-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T23:08:15Z","timestamp":1661900895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01848-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01848-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"29 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SRW is a former employee and stockholder of AstraZeneca and receives research funding from Cancer Research UK and Astex Pharmaceuticals. ID is an employee of Cancer Research UK which acquired the development rights to AZD3965 from AstraZeneca. JRM and CPV are employees of the MD Anderson Cancer Centre which holds the patent on IACS-010759. RAN, HT, YZ and RH were funded by Cancer Research UK. No disclosures were reported by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study did not involve human participants, human data or the acquisition of human tissue. All in vivo experiments conducted in mice were reviewed and approved by the relevant institutional animal welfare committees (Newcastle University Animal Welfare Ethical Review Board) and performed according to the Guidelines for the Welfare set out by an ad hoc committee of the National Cancer Research Institute (Workman et al. []) and national law (Animals (Scientific Procedures) Act (1986)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable to this study. All authors have reviewed the final version of the manuscript and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}